Ariadne.ai won a €518,000 grant to develop TumorTwin, a virtual 3D model built from spatial multiomics to simulate glioblastoma behavior and therapy responses. The company plans a prototype within a year and intends TumorTwin to predict tumor reactions to single or combination therapies for research and, eventually, clinical decision support. Ariadne.ai’s platform already integrates outputs from spatial biology instruments (CosMx, Phenocycler) and aims to combine image-based cell mapping with computational simulation. TumorTwin seeks to accelerate drug discovery and therapy selection for glioblastoma by leveraging spatial context—how cell types and molecular states are arranged in tissue—and building in silico experiments that complement wet-lab studies.